Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy

Cancer

Volumn 97, Issue 9 SUPPL., 2003, Pages 2374-2380

  Gajjar, Amar ^a   Chintagumpala, Murali M ^b   Bowers, Daniel C ^c   Jones Wallace, Dana ^a   Stewart, Clinton F ^a   Crews, Kristine R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

EIA; Intrapatient dosage escalation; Irinotecan; Pharmacokinetics

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; 7 ETHYL 10 [4 N (5 AMINOPEPTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; ANTICONVULSIVE AGENT; CARBAMAZEPINE; ENZYME INDUCING ANTICONVULSIVE AGENT; IRINOTECAN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANEMIA; AREA UNDER THE CURVE; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME INDUCTION; FEMALE; GLIOMA; HUMAN; HYPOKALEMIA; HYPONATREMIA; INFUSION; INTRAPATIENT DOSAGE ESCALATION; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; VOMITING;

EID: 0037403371     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11308     Document Type: Conference Paper

References (21)

1. Hare CB, Elion GB, Houghton PJ, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1997;39:187-191.
2. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem. 1989;32:715-720.
3. Zamboni WC, Gajjar AJ, Heideman RL, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res. 1998;4:783-789.
4. Minami H, Lad TE, Nicholas MK, et al. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. Clin Cancer Res. 1999;5:1325-1330.
5. Grossman SA, Hochberg F, Fisher J, et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The new approaches to brain tumor therapy. Cancer Chemother Pharmacol. 1998;42:118-126.
6. Crews KR, Stewart CF, Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res. 2002;8:2202-2209.
7. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516-1525.
8. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol. 1999;17:1815-1824.
9. Rodman JH, Murry DJ, Madden T, et al. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol. 1994;12:2390-2397.
10. Houghton PJ, Cheshire PJ, Hallman JD II, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995;36:393-403.
11. Crews KR, Stewart CF, Gajjar A. Lack of pharmacokinetic interaction between irinotecan and dexamethasone in pediatric patients with malignancies [abstract]. Clin Pharmacol Ther. 2002;71:31.
12. Schuetz EG, Schuetz JD, Strom SC, et al. Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology. 1993;18:1254-1262.
13. Fleishaker JC, Pearson LK, Peters GR. Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans - a putative measure of CYP3A induction. J Pharm Sci. 1995;84:292-294.
14. Sutherland L, Ebner T, Burchell B. The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol. 1993;45:295-301.
15. Doostdar H, Grant MH, Melvin WT, et al. The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HEPG2 hepatoma cells. Biochem Pharmacol. 1993;46:629-635.
16. Chu XY, Kato Y, Niinuma K, et al. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther. 1997;281:304-314.
17. Schellens JH, Maliepaard M, Scheper RJ, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci. 2000;922:188-194.
18. Maliepaard M, van Gastelen MA, Tohgo A, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res. 2001;7:935-941.
19. Chu XY, Kato Y, Sugiyama Y. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metab Dispos. 1999;27:440-441.
20. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996;49:311-318.
21. Kiuchi Y, Suzuki H, Hirohashi T, et al. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 1998;433:149-52.